{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05919147",
            "orgStudyIdInfo": {
                "id": "PBRC 2023-013"
            },
            "organization": {
                "fullName": "Pennington Biomedical Research Center",
                "class": "OTHER"
            },
            "briefTitle": "The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia",
            "officialTitle": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia",
            "acronym": "TRACE-1",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "the-neuroendocrine-effects-of-pioglitazone-in-patients-with-cancer-and-cachexia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-06-12",
            "studyFirstSubmitQcDate": "2023-06-22",
            "studyFirstPostDateStruct": {
                "date": "2023-06-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Justin Brown",
                "investigatorTitle": "Director, Cancer Metabolism Program",
                "investigatorAffiliation": "Pennington Biomedical Research Center"
            },
            "leadSponsor": {
                "name": "Pennington Biomedical Research Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is evaluate the effect of pioglitazone compared with placebo on skeletal muscle insulin sensitivity in subjects with cancer and cachexia."
        },
        "conditionsModule": {
            "conditions": [
                "Lung Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Pioglitazone",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Pioglitazone 45 mg"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Pioglitazone 45 mg",
                    "description": "The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.",
                    "armGroupLabels": [
                        "Pioglitazone"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo will have the same appearance as the active drug.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in skeletal muscle insulin sensitivity",
                    "description": "Quantified using hyperinsulinemic-euglycemic clamp",
                    "timeFrame": "Baseline, Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u226518 years\n* Documented histologic or cytologic diagnosis of non-small-cell lung cancer or gastrointestinal cancer that is locally advanced and inoperable or metastatic (e.g., spread to distant organs)\n* Cachexia defined by Fearon criteria\n* Insulin resistance syndrome, defined with the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)\n* Ability to provide written informed consent, willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures\n* Provide written approval by a qualified healthcare professional\n* Allow the collection and storage of biospecimens and data for future use\n\nExclusion Criteria:\n\n* Prior diagnosis of type 2 diabetes\n* Prior or current thiazolidinedione (TZD) therapy\n* Known hypersensitivity to TZD\n* New York Heart Association (NYHA) class I-IV heart failure\n* History of or actively treated bladder cancer\n* Current use of CYP2C inhibitor (e.g., gemfibrozil) or CYP2C inducer (e.g., rifampin)\n* Inadequate hepatic function\n* Currently pregnant, breastfeeding, or planning to become pregnant within the next 16 weeks\n* Contraindications to magnetic resonance imaging (e.g., implanted cardiac device, cochlear implant)\n* Any other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Justin Brown",
                    "role": "CONTACT",
                    "phone": "(225) 763-2715",
                    "email": "justin.brown@pbrc.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Pennington Biomedical Research Center",
                    "status": "RECRUITING",
                    "city": "Baton Rouge",
                    "state": "Louisiana",
                    "zip": "70808",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Justin Brown",
                            "role": "CONTACT",
                            "phone": "225-763-2715",
                            "email": "justin.brown@pbrc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.45075,
                        "lon": -91.15455
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002100",
                    "term": "Cachexia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000015431",
                    "term": "Weight Loss"
                },
                {
                    "id": "D000001836",
                    "term": "Body Weight Changes"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                },
                {
                    "id": "D000013851",
                    "term": "Thinness"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M21265",
                    "name": "Wasting Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M5363",
                    "name": "Cachexia",
                    "asFound": "Cachexia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                },
                {
                    "id": "M18102",
                    "name": "Weight Loss",
                    "relevance": "LOW"
                },
                {
                    "id": "M5115",
                    "name": "Body Weight Changes",
                    "relevance": "LOW"
                },
                {
                    "id": "M16614",
                    "name": "Thinness",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077205",
                    "term": "Pioglitazone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1693",
                    "name": "Pioglitazone",
                    "asFound": "Percutaneous",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}